RAMIRIS
- Status: aktiv, NCT03081143
- Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY
- Kurzinformation
- Ansprechpartner:
Prof. Dr. Gerald Illerhaus
Telefon: 0711 278-30401
E-Mail: g.illerhaus@klinikum-stuttgart.de - Studienzentrale
Telefon: 0711 278-30410, -30411, -30414
E-Mail: scc-studienzentrale@klinikum-stuttgart.de
NIS INGA
- Status: aktiv
- A national, prospective, non-interventional study (NIS) of nivolumab plus chemotherapy in first-line treatment of gastric, gastro-oesophageal junction or oesophageal adenocarcinoma and oesophageal squamous cell carcinoma (ESCC) and nivolumab plus ipilimumab in ESCC
- Kurzinformation
- Ansprechpartner:
Dr. Wolfram Bohle
Telefon: 0711 278-35125
E-Mail: w.bohle@klinikum-stuttgart.de - Studienzentrale
Telefon: 0711 278-30410, -30411, -30414
E-Mail: scc-studienzentrale@klinikum-stuttgart.de